FDA Approved Indications for this Orphan Drug:

Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion

FDA Marketing Approval issued as of:
01/29/2016

Orphan Drug exclusivity ends on:
N/A
Company Making and Marketing this drug:
Arbor Pharmaceuticals, Inc.

FDA Designation Date:
2/24/15

FDA Drug Designation:
Preventing hepatic injury from acetaminophin overdose